In a 68-year-old patient who is a Type 1 diabetic with schizophrenia, what long-term medication is associated with tardive dyskinesia?

Tardive dyskinesia is a potential long-term side effect primarily associated with first-generation antipsychotics, which are classic in their propensity to induce this condition. Chlorpromazine, commonly known as Thorazine, is a first-generation antipsychotic. It has been widely used in the treatment of schizophrenia and other psychiatric disorders.

This medication works by antagonizing dopamine receptors in the brain, which can lead to an imbalance in neurotransmission in the long term, causing symptoms such as repetitive, involuntary movements typically seen in tardive dyskinesia. This condition can be particularly problematic, as it may not be reversible even after discontinuation of the drug.

In contrast, the other options listed are classified as second-generation antipsychotics or atypical antipsychotics. While these medications can still have side effects, they are generally associated with a lower risk of tardive dyskinesia compared to first-generation antipsychotics. This understanding aids in recognizing the risks associated with different classes of medications when treating patients with psychiatric conditions, such as schizophrenia, especially in older adults who may have additional health considerations, such as diabetes.